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Background: Non-invasive prenatal screening (NIPS) for fetal chromosome abnormalities using cell-free
deoxyribonucleic acid (cfDNA) in maternal serum has significantly influenced prenatal diagnosis of fetal
aneuploidies since becoming clinically available in the fall of 2011. High sensitivity and specificity have
been reported in multiple publications, nearly all of which have been sponsored by the commercial performing
laboratories. Once results are returned, positive and negative predictive values (PPVs, NPVs) are the performance
metrics most relevant to clinical management. The purpose of this report is to present independent data on
the PPVs of NIPS in actual clinical practice.
Methods: Charts were retrospectively reviewed for patients who had NIPS and were seen March 2012 to December
2013 in a tertiary academic referral center. NIPS results were compared to diagnostic genetic test results, fetal ultrasound
results, and clinical phenotype/outcomes. The PPV was calculated using standard epidemiological methods. Correlation
between screen results and both maternal age at delivery and gestational age at time of screening was assessed using
Wilcoxon’s rank sum test.
Results: Of 632 patients undergoing NIPS, 92 % of tests were performed in one of the four major commercial
laboratories offering testing. However, all four laboratories are represented in both the normal and abnormal
results groups. There were 55 abnormal NIPS results. Forty-one of 55 abnormal NIPS results were concordant
with abnormal fetal outcomes, 12 were discordant, and 2 were undetermined. The PPV for all conditions included in
the screen was 77.4 % (95 % CI, 63.4 – 87.3). Of 578 patients with normal NIPS results, normal pregnancy outcome was
confirmed for 156 (27 %) patients. This incomplete follow-up of normal NIPS results does not affect PPV calculations,
but it did preclude calculations of sensitivity, specificity, and NPV. Maternal age at delivery was significantly lower
for patients with abnormal discordant results, compared to patients with abnormal concordant results (P = 0.034).
Gestational age at time of screening was not associated with concordance of screen results (P = 0.722).
Conclusions: The experience of using NIPS in clinical practice confirms that abnormal results cannot be considered
diagnostic. Pre-test counseling should emphasize this. Diagnostic genetic testing should always be offered following
abnormal NIPS results.
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Cell-free deoxyribonucleic acid (cfDNA) refers to fragments
of DNA circulating freely in the plasma. The fragments are
most frequently 150-180 base pairs in length [1, 2] and
derive mostly from apoptotic cells [2]. During preg-
nancy, placental cytotrophoblastic cells are shed into
maternal circulation and contribute to the cfDNA pool in
the maternal bloodstream [3]. After 10 weeks gestation, an
average of 10 % of maternal cfDNA is placental in origin
[4]. Non-invasive prenatal screening (NIPS) for fetal
chromosome abnormalities is based on either massively
parallel sequencing [5–11] or analysis of single nucleotide
polymorphism (SNP) patterns [12, 13] from cfDNA in
maternal serum. Very high sensitivity (98.6 - 100 %)
and specificity (99.7 - 100 %) have been reported in
multiple clinical validation studies of NIPS for Down
syndrome (DS) [6, 9, 10, 12, 14]. Somewhat lower sensitiv-
ities and specificities are seen when screening for trisomy
18 (T18), trisomy 13 (T13), and the sex chromosome
aneuploidies (SCAs: 45,X; 47,XXX; 47,XXY; 47,XYY)
[7–11, 13–17].
Although sensitivity and specificity are important
performance metrics, positive predictive value (PPV) and
negative predictive value (NPV) become more clinically
relevant after results have returned. Although some publi-
cations sponsored by commercial laboratories performing
NIPS have included PPV and NPV [10, 14, 18, 19], there is
minimal independent data available on the performance of
NIPS in actual clinical practice [20–23].
Here we present our first two years’ experience with
NIPS in a tertiary referral center. Performance was eval-
uated by calculating standard metrics such as PPV.
Underlying biological causes for discordant results were
determined where possible. Some discordant or unusual
cases are described in detail. Benefits and limitations of
using NIPS in clinical practice and recommendations for
follow-up of abnormal results are discussed.
Methods
This study was approved by the Human Subjects Division
(Application no. 47,683) and the Institutional Review Board
(IRB) at the University of Washington Medical Center
(UWMC). The requirement to obtain written consent and
the requirement for Health Insurance Portability and Ac-
countability Act (HIPAA) authorization were both waived
by the IRB. Medical records were retrospectively reviewed
for 632 consecutive patients who had NIPS and were seen
between March 2012 and December 2013 in the Prenatal
Genetics and Fetal Therapy (PGFT) Program, a tertiary
referral center for prenatal genetic counseling and prenatal
diagnosis located at UWMC. Patient age at delivery,
gestational age at screening, indication for screening, and
maternal serum screen results were extracted from out-
patient clinic notes. Pregnancy outcomes were extractedfrom delivery summaries. Fetal ultrasound results were ex-
tracted from radiology records; diagnostic genetic test re-
sults were extracted from cytogenetics records; and NIPS
results were extracted from laboratory records. Of the 632
patients undergoing NIPS, 92 % of the tests were per-
formed in one of the four major commercial laboratories
offering testing during this timeframe.
Patients with normal NIPS results typically declined
prenatal diagnostic genetic testing. If not already com-
pleted, maternal serum alpha-fetoprotein (AFP) and fetal
anatomy ultrasound were recommended, and the patient
was referred back to her primary obstetrical provider for
routine care. Patients with abnormal NIPS results were
offered high-resolution fetal ultrasound interpreted by
either a UWMC perinatologist or a UWMC radiologist
specializing in fetal anatomical imaging, genetic counseling,
and prenatal diagnostic genetic testing via chorionic villus
sampling (CVS) or amniocentesis. When the latter was
declined, postnatal testing was recommended. Maternal
chromosome analysis was added to our recommendations
several months after we started to offer NIPS. For all pa-
tients, follow-up care recommendations were communi-
cated verbally to the patient at the time of the NIPS results
disclosure and/or genetic counseling consult, and in writing
to the referring provider.
Normal NIPS results were defined as concordant when
either diagnostic genetic test results matched the screen
results or, for patients declining prenatal diagnostic genetic
testing and delivering at UWMC, when normal pregnancy
outcome was confirmed by review of delivery records.
Newborn exams were performed by pediatricians. For
patients with normal NIPS results who declined prenatal
diagnostic genetic testing and delivered elsewhere, preg-
nancy outcomes were not confirmed. Abnormal NIPS re-
sults were defined as concordant when either diagnostic
genetic test results matched the screen results or when
multiple other clinical findings (such as fetal ultrasound
abnormalities) corroborated the screen results. Nuchal
translucency (NT) was defined as abnormal when the
DS likelihood ratio was ≥ 2 [24]. Patients who declined
diagnostic genetic testing and were lost to follow-up
with incomplete clinical information were not included
in calculations of test performance. Diagnostic genetic
test methods included interphase fluorescence in situ
hybridization (IFISH), karyotyping, and cytogenomic
microarray analysis (CMA). Diagnostic genetic testing was
performed by the University of Washington Cytogenetics
and Genomics Laboratory unless otherwise stated.
The R statistical software package (version R 2.12.0)
[25] and Excel were used for all statistical analyses. For
categorical data, frequencies or percentages with 95 %
confidence intervals were derived. For quantitative data,
means with standard deviations, medians with minimum
and maximum values, and frequencies were calculated.
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significance between groups, and P-values of ≤0.05 were
considered statistically significant. The PPV was calculated
with standard methods [26]. The reported performance of
NIPS is remarkably similar across all test platforms in
studies sponsored by the commercial laboratories [6, 9, 10,
12, 14, 19], so all NIPS results for this cohort were




Of 632 patients, most were at increased risk for fetal aneu-
ploidy as defined by American Congress of Obstetricians
and Gynecologists guidelines [27]. Frequent indications for
NIPS included maternal age ≥35 at delivery, abnormal
serum screen results, fetal ultrasound abnormalities, and
family or personal history of a previous child with aneu-
ploidy (Fig. 1). To determine whether concordance of NIPS
results was correlated with maternal age at delivery or ges-
tational age at screening, medians and their distributions
were plotted and assessed for statistical significance (Fig. 2,
Table 1). Maternal age at delivery was significantly older for
patients with abnormal concordant results compared to
patients with abnormal discordant results (P = 0.034) and
to patients with normal results (P = 0.009). Gestational
age at screening ranged from 9.9 to 33.6 weeks and was
not significantly associated with concordance of results.
PPV of NIPS in an independent clinical setting
Figure 3 shows the breakdown of NIPS results for this
patient cohort. Of 632 patients offered NIPS, no results
were obtained for one patient, giving a test failure rate of
0.16 %. No redraws were needed in this cohort. Fifty-three
of 631 (8 %) patients had abnormal NIPS results. This
relatively high percentage reflects our high-risk patient





Fig. 1 Indications for NIPS. Abbreviations: NIPS, non-invasive prenatal screechromosomes. One had abnormal results for DS and
47,XXX, and one had abnormal results for T18 and DS.
Among 55 abnormal NIPS results, 41 were concordant,
2 were undetermined and lost to follow-up, and 12 were
discordant with diagnostic genetic testing and/or clinical
phenotype (Fig. 3). Table 2 summarizes the clinical details
of the 12 patients with discordant results. The overall PPV
for all disorders included in the screen was 77.4 % (95 %
CI, 63.4 - 87.3). The highest PPV was for DS (90.3 %, 95 %
CI 73.1 - 97.5). NIPS for T18 had the second highest PPV
at 63.6 % (95 % CI 31.6 - 87.6). The PPVs for the combined
SCAs and for T13 were lowest, at 55.6 % (95 % CI 22.6 -
84.6) and 50 % (95 % CI 2.7 - 97.3), respectively. If the 8
abnormal NIPS results that were compared to phenotype
and clinical outcomes, instead of diagnostic genetic test
results, are excluded, the overall PPV was 82.9 % (95 %
CI 68.6 - 91.9) in this cohort.
Sex assessment
NIPS results can also include fetal sex assessment, rais-
ing the possibility of normal results that are discordant
for sex. We are aware of a single instance of normal
NIPS results discordant for fetal sex during this time-
frame. Patient 60 was a 26-year-old who presented at
12.4 weeks for routine aneuploidy screening. She had a
personal history of congenital unilateral renal agenesis
with contralateral damage secondary to reflux. She had
undergone a renal transplant from a male donor three
years prior. NIPS results were normal and consistent
with a male fetus. During pre-test counseling and again
when she was informed of the results, she was cautioned
that the sex assessment may not be accurate in her case.
Fetal anatomy ultrasound at 21.4 weeks showed female
genitalia. She was counseled that the likely explanation
for the gender discordance was that her cfDNA pool
included Y chromosome DNA from the transplanted
kidney. She declined amniocentesis for prenatal geneticMaternal Age > 35 at Delivery
Maternal Serum Screen 
Positive for Aneuploidy
Ultrasound Abnormality
Patient Request for NIPS
Family History of Aneuploidy
Previous child with Aneuploidy
Other
ning
Fig. 2 Median and distribution of a maternal age at delivery and b gestational age at NIPS. P-values based on Wilcoxon’s rank sum test (*P < 0.05,
**P < 0.01). Abbreviations: NIPS, non-invasive prenatal screening
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external genitalia at birth. Karyotyping was not considered
indicated and was not done prior to discharge.
Follow-up after normal NIPS results
Of 578 patients with normal NIPS results, 22 (4 %) had
diagnostic genetic testing, the results of which were con-
cordant in all cases for the chromosomes screened
(Fig. 4). Diagnostic genetic testing was done postnatally
on cord blood in 9 of the 22 cases secondary to congenital
anomalies detected prenatally by ultrasound. In the other
13 cases, the patient chose to have prenatal testing by
amniocentesis. Among these 13 patients, 3 opted for
diagnostic testing after subsequent fetal anatomy ultra-
sound revealed anatomical anomalies; 5 stated an upfront
preference for diagnostic genetic testing, but felt CVS was
too risky, and used NIPS to assess fetal status at an early
gestational age; 3 changed their minds during the prenatal
genetic evaluation process and decided they preferredTable 1 Maternal age at delivery and gestational age at time of NIP
Maternal age (years) I. Abnormal concordant
II. Abnormal discordant
III. Normal concordant
Gestational age (weeks) I. Abnormal concordant
II. Abnormal discordant
III. Normal concordant
aP-values calculated using Wilcoxon rank sum test
*P < 0.05
**P < 0.01diagnostic testing; and the remaining 2 patients had un-
usual, unique, clinical circumstances that influenced their
decision to pursue prenatal diagnostic genetic testing. Of
patients with normal NIPS results who had no diagnostic
genetic testing, 134 (23 %) had a normal pregnancy out-
come confirmed by review of UWMC delivery records.
Pregnancy outcome was not confirmed for the 422 (73 %)
patients delivering elsewhere.
Follow-up after abnormal NIPS results
Fifty-three of 632 patients had abnormal NIPS results
and were offered genetic counseling and follow-up testing.
Figure 5 outlines patient decisions and outcomes after ab-
normal NIPS results. Follow-up fetal ultrasound results
were normal in 12 of 53 (23 %) patients with abnormal
NIPS results. NIPS results were discordant in 8 of 12
(67 %) patients with normal follow-up fetal ultrasound
results (Fig. 5, b and c). Fetal ultrasound anomalies
were seen in the other 41 (77 %) patients with abnormalS, stratified by NIPS results
Median Mean SD P-valuesa
39.00 36.97 6.13 I vs. III 0.009**
34.00 33.08 4.70 I vs. II 0.034*
36.00 34.79 5.16 II vs. III 0.161
13.10 14.94 3.74 I vs. III 0.156
14.10 15.76 4.17 I vs. II 0.722
13.25 15.64 3.97 II vs. III 0.627
631 patients with 
NIPS resultsa 
578             
Normal
53 (55)            
Abnormalb
33 Abnormal for  
Down syndrome
28 Concordant     
3 Discordant        
2 Undetermined
11 Abnormal for  
trisomy 18
7 Concordant      
4 Discordant
2 Abnormal for  
trisomy 13
1 Concordant      
1 Discordant
9 Abnormal for  
sex chromosome  
aneuploidies 
5 Concordant    
4 Discordant 
Fig. 3 NIPS results for this cohort. aSex chromosome aneuploidies were included in only 520 patients. bTwo patients had abnormal results for
two different chromosomes. Abbreviations: NIPS, non-invasive prenatal screening
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(10 %) patients with abnormal follow-up fetal ultrasound
results (Fig. 5 e, g, and h), excluding the 2 undetermined
cases (Fig. 5j).
A genetic diagnosis was obtained in 45 (85 %) patients
(Fig. 6). Twenty-two of 45 patients (49 %) chose prenatal
diagnostic genetic testing (Fig. 5). Thirteen of these pa-
tients had concordant abnormal karyotype results and
chose termination of pregnancy (TOP) (Fig. 5, a and d).
The other 9, including 5 patients with discordant normal
karyotype results (Fig. 5, b and e) and 4 patients with
concordant abnormal karyotype results (Fig. 5, a and d),
continued to term. Twenty-three of 45 patients (51 %)
declined prenatal diagnostic testing, and postnatal test-
ing was done instead (Fig. 5). Seven patients had an
intrauterine fetal demise (IUFD) or neonatal demise
(Fig. 5f ). Seven patients opted for TOP after follow-up
fetal anatomy ultrasound revealed anomalies consistent
with the condition suggested by their NIPS results.
Among these 14 patients, NIPS results were concordant
with diagnostic genetic testing of fetal tissue in 14 of 15
instances. The single discordance occurred in a patient
whose NIPS result was abnormal for both T18 and DS
(Fig. 5g), as IFISH of fetal tissue showed two signals for
chromosome 21 and three signals for chromosome 18.
Nine patients continued to term. Neonatal peripheral
blood karyotype results were concordant with NIPS
results in 7 of these 9 cases (Fig. 5h).
For 8 patients who declined both prenatal and postnatal
genetic testing, NIPS results were compared to clinical out-
comes to evaluate concordance. Two of the 8 patients (one
DS and one 45,X) had fetal ultrasonographic anomalies
consistent with the condition suspected by NIPS, declinedprenatal diagnostic genetic testing, had an IUFD, and
declined postnatal genetic testing (Fig. 5i). These cases
were considered concordant, because the probable
diagnosis based on fetal anatomy ultrasound abnormalities
matched the diagnosis suspected from NIPS results. Four
of the 8 patients (3 T18, 1 DS) had normal follow-up fetal
anatomy ultrasound results and declined prenatal diag-
nostic genetic testing (Fig. 5c). Newborn clinical exams
performed by pediatricians were normal in all 4 cases,
and postnatal genetic testing was not considered indi-
cated. These cases were considered discordant because
of the low likelihood that a newborn affected with T18
or DS would be phenotypically normal at delivery. Two
patients with DS NIPS results had abnormal follow-up
NT results, declined all further services, and opted for
TOP (Fig. 5j).
Discussion
Publications regarding the performance of NIPS have
mostly been sponsored by the commercial laboratories
performing the test [10, 14, 18, 19, 28]. To our knowledge,
this is the largest independent report of clinical experience
using NIPS in a tertiary referral center in the United
States. During the first two years of offering NIPS, we
witnessed the powerful benefits of this technology.
First, multiple studies have shown that NIPS has a very
high NPV, including a recently published prospective
multicenter study that found an NPV of 100 % for DS
[19]. Indeed, we are not aware of any normal discordant
results among this patient cohort during this timeframe
(Fig. 3). Normal NIPS results thus do greatly reduce the
probability of a fetus affected with the conditions included
in the screen. Whether NIPS is done as a primary screen
Table 2 Details of discordant cases
Patient NIPS
result
Other clinical information Fetal diagnostic genetic test results Maternal results
31 Abnormal
for DSa
US at 19.3w multiple anomalies consistent
with T18
nuc ish (D21S259x2) on FFPE fetal tissue Not offered
32 Abnormal
for DS
US at 12.3w abnormal NT; US at 20.7w
normal; postpartum note “delivered a





Paternal first cousin with DS; US at 13.4w
normal NT; US at 16.6w normal
46,XY in all 15 amniocyte clones; arr(1-22)x2,(XY)x1
on amniocytes
46,XX in all 20 peripheral
blood cells analyzed and 30
additional cells screened for 21
41 Abnormal
for T18
AMA; FTS pos DS (1 in 43); US at 13.1w




AMA; US at 19.6w normal nuc ish(D18Z1x2)[200/200] on uncultured









US at 19.0w EIF; discharge exam: “Baby
does not have any physical exam findings




AMA; US at 13.7w normal NT; US at
20.4w normal
nuc ish(RB1x2)[50/50] on uncultured amniocytes;
46,XX in all 15 amniocyte clones
46,XX in all 20 peripheral
blood cells analyzed and 50
additional cells screened for 13
51 Abnormal
for 45,X
AMA; US at 19.3 normal nuc ish(DXZ1x2), (DYZ3x0)[191/200]; 46,XX in all 21





AMA; US at 12.3w normal NT; US at
20.3w normal
nuc ish(DXZ1x2)[220/225], (DYZ3x0)[225/225] on
uncultured amniocytes; 46,XX in all 16 amniocyte
clones analyzed and 22 additional clones screened
for 45X
46,XX in all 20 peripheral
blood cells analyzed and 30
additional cells screened for X
55 Abnormal
for 47,XXX
US at 18.8w unilateral CPC and unilateral
renal pelviectasis
46,XX in all 20 cells analyzed from peripheral
blood postnatally
46,XX in all 20 peripheral
blood cells analyzed and 30
additional cells screened for X
56 Abnormal
for 47,XXX
Quad screen pos DS 1 in 15, maternal
diabetes and renal failure, US at 21.3w
two-vessel cord
46,XX in all 20 cells analyzed from peripheral
blood at 7 weeks of age
Not done secondary to
chaotic family circumstances
Abbreviation: AMA advanced maternal age, CPC choroid plexus cyst, DS Down syndrome, EIF echogenic intracardiac focus, FFPE formalin-fixed, paraffin-embedded,
FTS first trimester (maternal serum) screen, NT nuchal translucency, T18 trisomy 18, T13 trisomy 13, US ultrasound
aResults were also abnormal for T18
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ultrasound findings, normal results provide reassurance.
Consequently, our rate of amniocentesis dropped signifi-
cantly, a trend reported by others [20, 29–31]. In this
series, 2 % of patients with normal NIPS results chose pre-
natal diagnostic genetic testing, as compared to 42 % of
patients with abnormal results (Figs. 4 and 5).
Second, NIPS proved to be an invaluable tool for pa-
tients wanting to learn as much as possible about fetal
health prior to delivery without incurring the miscarriage
risk associated with CVS and amniocentesis. These pa-
tients commonly expressed that they would not consider
TOP, regardless of the diagnosis. Even if NIPS results were
abnormal, the family would benefit from being able to
prepare for delivery with greater certainty about what
lay ahead. In our cohort, this use of NIPS was especially
obvious among patients confronted with abnormal findings
on their mid-trimester fetal anatomy ultrasound, typicallydone at 18-22 weeks. Several of our patients in this
situation voiced understanding that NIPS results are
not diagnostic and still chose NIPS instead of diagnostic
genetic testing (Fig. 1). Abnormal fetal ultrasound was the
most frequent indication for NIPS (66 %) among patients
drawn after 20 weeks.
Our experience also confirmed the limitations of NIPS.
First, only a handful of conditions are included in the
NIPS panels, so normal results only lower the likelihood
of the fetus being affected with those disorders. In this
cohort, patient 58 was a 35-year-old who presented at
13 weeks for routine screening. The NT measurement
was markedly abnormal. The couple opted for NIPS,
which returned with normal results. Fetal ultrasound at
16.3 weeks showed echogenic bowel, a two-vessel cord,
unilateral clubfoot, unilateral renal agenesis, and an atrial
septal defect. CMA and karyotyping of amniocytes showed

































Normal Outcome by 
Review of Delivery 
Records
422
Delivered Elsewhere     
Normal Outcome       
Not Confirmed
Fig. 4 Follow-up after normal NIPS results. Abbreviations: CVS, chorionic villus sampling; NIPS, non-invasive prenatal screening
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should still be offered a fetal anatomy ultrasound to
screen for congenital abnormalities.
Second, although normal discordant NIPS results are
rare with such a high NPV, they do occur. Reports of
“false negatives” have started to appear [32, 33], as the
number of patients having NIPS has increased. Since
data collection ended for this cohort, we have had one
normal discordant result in a 34-year-old who presented
at 13 weeks for routine screening. The NT measurement
was enlarged. NIPS results were normal, but karyotyping
of fetal tissue revealed 47,XY,+21 in all cells.
Third, abnormal NIPS results confer a high risk, but
not a diagnosis, of a fetal abnormality. The PPV was
77.4 % (95 % CI 63.4 - 87.3) in this cohort for all condi-
tions included in the NIPS panels. We also observed
that the PPVs differed in this cohort for each condition
included in NIPS. Abnormal results for DS were the
most frequent, and these results had the highest PPV.
T18 was the next most frequent condition, and results
had the second highest PPV. Abnormal results for the
combined SCAs and T13 were the least frequent and had
the lowest PPVs. This matches trends in the published
literature [10, 14, 18, 28, 34]. There may be multiple
reasons for this. T13 and T18 are less prevalent than
DS, which would adversely impact the PPV. Confined
placental mosaicism (CPM) for a trisomic cell line was
observed more frequently at CVS for chromosomes 13
and 18 than for chromosome 21 [35, 36]. Postzygotic
loss (“trisomy rescue”) in a trophectoderm progenitorcell, leading to placental mosaicism for euploidy, was
hypothesized to facilitate the intrauterine survival of T13
and T18 conceptuses [37]. The percentage of placental
DNA in maternal circulation is generally lower when the
fetus has T18, T13, or 45,X and higher when the fetus has
DS [4, 28, 38].
There are several causes of discordant results. Discordant
results may be caused by statistical limitations of the
analysis algorithms and/or uneven sequencing coverage
secondary to guanine and cytosine (GC) content differ-
ences between chromosomes [39, 40]. PPV and NPV
are influenced by the prevalence of the condition in the
screened population. As expected in this cohort, maternal
age at delivery was significantly younger among patients
with abnormal discordant results, compared to patients
with abnormal concordant results (Fig. 2a). Other studies
have also shown a drop in PPV when women of all levels of
risk are included, as compared to a solely high-risk popula-
tion [14, 28]. Normal discordant results have been reported
to be more likely at an early gestational age because of a
lower placental cfDNA fraction [6, 7]. Gestational age at
time of screening was not associated with concordance of
results in our series (Fig. 2b), but we do not have data on
body mass index and placental cfDNA fraction. Maternal
mosaicism was detected in several instances of discordant
NIPS results abnormal for an SCA [34, 41] and has also
been reported for T18 [21]. Patient 51 (Table 2) was an
example of this. Maternal chimera due to prior organ
transplant was the likely cause of gender discordance for
patient 60 (described above). CPM can cause discordant
Fig. 5 Patient decisions after abnormal NIPS results and clinical outcomes. aOne patient had abnormal results for two different chromosomes
(DS, XXX); both results were concordant. bOne patient had abnormal results for two different chromosomes; one result was concordant (T18)
and one was discordant (DS). Abbreviations: DS, Down syndrome; IUFD, intrauterine fetal demise; NIPS, non-invasive prenatal screening; SCA,




















Fig. 6 Diagnostic genetic testing after abnormal NIPS results. Abbreviations: NIPS, non-invasive prenatal screening
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during gestation is the placental cytotrophoblastic cell line.
Aneuploidy in the cytotrophoblastic cell line with a diploid
fetus may cause an abnormal discordant NIPS result,
whereas diploidy in the cytotrophoblastic cell line with a
trisomic fetus may cause a normal discordant NIPS result
[32, 42–44]. There are several case reports of discordant
NIPS results in pregnancies with proven CPM [33, 45–49].
Placental testing was not done in this cohort, because
management is not influenced by results, but CPM may
explain the discordant results in patient 46 (Table 2).
Other biological reasons for discordant results include a
vanishing twin with aneuploidy and maternal metastatic
disease [50].
Apparent sex discordance can have a variety of causes,
including inaccurate sex assessment on ultrasound, a co-
twin demise, the statistical limitations of NIPS, and a
fetus affected with one of the various disorders of sexual
development. NIPS did not include the option of fetal
sex assessment during the entire timeframe reported
here, and not all patients chose to learn the predicted
fetal sex from NIPS. Nevertheless, we are aware of only
one instance of confirmed fetal sex discrepancy, in a pa-
tient who had a personal history of a renal transplant
from a male donor.
Thus, it is imperative that providers make every effort
to confirm NIPS results that are abnormal or appear
discordant for fetal sex. Ideally, confirmation would be
with diagnostic genetic testing done prior to making any
irrevocable decisions about pregnancy management.
Twenty-two families (42 %) in this cohort with abnormal
NIPS results chose to have prenatal diagnostic genetic
testing (Fig. 5a, b, d, e and Fig. 6). Nine patients in this
group continued to term and took advantage of all oppor-
tunities to gain information about fetal health during their
pregnancies. However, patients may decline prenatal
diagnostic testing after an abnormal NIPS result, as did
31 (58 %) patients in this series. Patients incorporate
other clinical information about fetal status into their
decision-making. If serum screen results, NIPS results,
and fetal anatomy ultrasound results all suggest the
same diagnosis, the patient may not need further con-
firmation. Or a patient’s concern about the suspected
condition may not be sufficient to warrant the risk of
the invasive procedures needed for prenatal diagnosis.
And many patients pursue prenatal genetic screening
to be better prepared for the birth, and would never
incur the risk of a prenatal invasive procedure, regardless
of NIPS results. Twenty-two patients in this cohort with
abnormal NIPS results (41 %) declined prenatal diagnostic
genetic testing with the intention of continuing to term
(Fig. 5c, f, h, and i).
Counseling patients about abnormal NIPS results is
complex. The likelihood of an affected fetus depends ona priori risk and is influenced by what else is known
clinically. For example, in this cohort, abnormal NIPS
results were more likely to be discordant when fetal
anatomy ultrasound was normal (67 %) than when ab-
normalities were seen (10 %). Determining appropriate
follow-up is also complicated. In some cases, doing a
CVS to obtain diagnostic genetic test results may be the
best approach, but it is problematic for several reasons.
Since the non-maternal component of cfDNA during
pregnancy is the placental cytotrophoblast, genetic test-
ing via CVS is a repeat analysis of the same tissue type.
If CVS reveals mosaicism, amniocentesis is recom-
mended, and the pregnancy is subjected to two invasive
procedures. Cytotrophoblasts are used for karyotyping in
direct and short-term culture after CVS. Results from
long-term CVS culture are generally based on analysis of
the villi mesenchymal cores. Recommendations are to
analyze both direct and long-term culture for the most
accurate results [35, 36]. Even so, CVS may not reveal
CPM, as only a small portion of the placenta is biopsied
during the procedure. Select portions of the placenta
may preferentially release cells into maternal circulation
[48], and these may not be the same regions sampled by
CVS. Patients should be counseled carefully about these
limitations.
Multiple methods for diagnostic genetic testing are
available. Karyotyping provides both numerical and
structural information and distinguishes free trisomy
from an unbalanced Robertsonian translocation. The latter
can be inherited, with significantly increased recurrence
risks when one parent is a carrier. However, chromosomal
microdeletions have been added to NIPS panels, and these
are typically undetectable with karyotyping. IFISH and
CMA can detect both submicroscopic changes and aneu-
ploidy, and these methods are more successful at obtain-
ing a diagnosis from non-viable, frozen, or formalin-fixed,
paraffin-embedded (FFPE) tissue [51]. But IFISH and
CMA do not reveal structural rearrangements, such as un-
balanced Robertsonian translocations causing DS.
Maternal karyotyping should be offered after abnormal
NIPS results to rule out maternal mosaicism, especially
when an SCA is suspected. Beyond possibly providing
an explanation for abnormal NIPS results in a current
pregnancy, patients with mosaicism are not good candi-
dates for using NIPS in subsequent pregnancies.
For the 632 patients undergoing NIPS, 92 % of the
tests were performed in one of the four major commercial
laboratories offering testing during this timeframe. Al-
though the results mainly reflected one commercial lab
doing NIPS, all four of those laboratories were represented
in both the normal and the abnormal results groups of the
cohort. In addition, the published performance of NIPS is
remarkably similar across all test platforms in studies spon-
sored by the commercial laboratories [6, 9, 10, 12, 14, 19].
Neufeld-Kaiser et al. BMC Medicine  (2015) 13:129 Page 10 of 11Thus, the main emphases of this report, that the PPV
of NIPS is less than 100 % and abnormal results should
be confirmed by diagnostic testing, apply to all NIPS
platforms and methods currently in use.
A limitation of this report is that normal pregnancy
outcome was not confirmed for 73 % of patients with
normal NIPS results. This precluded us from calculating
sensitivity, specificity, or NPV for this cohort. However,
the PPV of NIPS, the main focus of this report, is un-
affected by outcomes of patients with normal NIPS results.
Our center does not routinely collect outcome data for pa-
tients referred to us who do not deliver at our hospital,
which is not unusual in a busy clinical practice. Based on
our past experience with referral providers, we feel it likely
that we would have been informed of any normal discord-
ant result uncovered by the birth of a child affected with
T13, T18, or DS. However, a normal discordant result
could have remained undetected if a patient experienced a
spontaneous pregnancy loss, and no postnatal genetic test-
ing was done.
Conclusions
NIPS for fetal chromosome abnormalities using cfDNA
in maternal serum is a powerful tool. It can be of enormous
benefit to patients seeking information about fetal health.
But with a PPV of less than 100 %, abnormal results cannot
be considered diagnostic. Most ordering providers will not
have time for a detailed discussion of sensitivity, specificity,
PPV, and NPV when talking with patients about prenatal
genetic screening options. At a minimum, providers should
emphasize that 1) normal discordant results, though
rare, do occur and 2) there are multiple possible explana-
tions for an abnormal NIPS result. While an affected fetus
is a common cause, it is not the only one. Management of
an abnormal NIPS result is complex, and these patients
should always be referred to a center offering genetic
counseling, high-resolution fetal ultrasound, and diagnostic
genetic testing.
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